ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Metropolis Healthcare earnings call we streamed: the live audio and our summary of what management said.
Metropolis delivered a robust 16% revenue growth, beating prior 12-13% organic guidance. Operating leverage is kicking in, with H1 margins expanding 190 bps despite heavy monsoon headwinds and no price hikes.
Metropolis delivered a robust 16% revenue growth, beating prior 12-13% organic guidance. Operating leverage is kicking in, with H1 margins expanding 190 bps despite heavy monsoon headwinds and no price hikes.
EBITDA margins guided to expand 125-170 bps for FY27; price hike planned for Q4 FY27.
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
Metropolis Healthcare reports strong FY26 performance with 23.6% YoY revenue growth and 24.4% EBITDA margin. Strategy focuses on network productivity, genomics, and expanding 'mini hubs' for pathology and basic radiology.
Metropolis Healthcare shows strong organic momentum, beating FY26 revenue guidance. Management is shifting focus from aggressive lab expansion to productivity-led growth and margin recovery through operating leverage.
Metropolis Healthcare reports strong FY26 growth, with Group Revenue up 24% and PAT up 31% YoY. The company is executing its 'Metropolis 3.0' strategy focused on specialty tests and network expansion.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.